CTOs on the Move

Epic Sciences

www.epicsciences.com

 
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Jason Christiansen
Chief Technology Officer Profile
Chockalingam Palaniappan
Chief Technology Officer Profile
Dave Henderson
Chief Information Officer Profile
Dave Henderson
Chief Information Officer Profile
Michael Giske
Chief Information Officer Profile

Funding

Epic Sciences raised $15M on 06/01/2015
Epic Sciences raised $40M on 04/28/2017
Epic Sciences raised $43M on 06/01/2022

Similar Companies

Parental Therapy Associates

Parental Therapy Associates is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

moksha8 Pharmaceuticals

moksha8 Pharmaceuticals is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Actym Therapeutics

Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.

ProtonDx

Because your organisation needs certainty when testing for Covid-19